Novartis hasn't been shy about digital. The Swiss drugmaker has rolled out app after app to help patients track their symptoms and stay on their drugs. But CEO Joe Jimenez says the company is about to do a lot more than that.
As hospitals scramble to reduce readmissions, or face punishment under the Affordable Care Act's Hospital Readmissions Reduction Program, they are increasingly turning to efficiency-promoting devices like St. Jude Medical's CardioMEMS HF System for monitoring heart failure patients.
Cynapsus Therapeutics touted the results of its Phase 2 clinical trial of its sublingual thin-film-strip formulation of apomorphine for the management of OFF motor symptoms of Parkinson's disease.
Researchers at the University of California in San Diego have developed a way to disguise the genetic material itself so that it can enter cells and shut down genetic diseases at the core.
Clovis Oncology has signed a deal to test whether its lead drug can make a difference in lung cancer when paired with GlaxoSmithKline's melanoma treatment Mekinist.
The Tufts Center for the Study of Drug Development created the industry standard on R&D budgets when it pegged average R&D costs at close to $1 billion for each new drug. Today, Tufts researchers updated their figures and boosted the total to $2.9 billion.
The National Science Foundation this week awarded a second research grant to the maker of the only FDA-cleared catheter for rectal delivery of medication and liquids to expand the device's use beyond the hospice.
Dubbed Intellia Therapeutics, the new company has come up with a $15 million bankroll in a Series A provided by the venture group and the Big Pharma outfit, which is intrigued by the potential this gene editing technology could play in two of the hottest fields in oncology.
Novartis continued to build its case for secukinumab (AIN457), an IL-17A inhibitor in development for a range of inflammatory conditions.
Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.